↓ Skip to main content

Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin…

Overview of attention for article published in Arthritis Research & Therapy, October 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study
Published in
Arthritis Research & Therapy, October 2015
DOI 10.1186/s13075-015-0795-y
Pubmed ID
Authors

Eirik Ikdahl, Jonny Hisdal, Silvia Rollefstad, Inge C. Olsen, Tore K. Kvien, Terje R. Pedersen, Anne Grete Semb

Abstract

Endothelial dysfunction is an early step in the atherosclerotic process and can be quantified by flow-mediated vasodilation (FMD). Our aim was to investigate the effect of long-term rosuvastatin therapy on endothelial function in patients with inflammatory joint diseases (IJD) with established atherosclerosis. Furthermore, to evaluate correlations between change in FMD (ΔFMD) and change in carotid plaque (CP) height, arterial stiffness [aortic pulse wave velocity (aPWV) and augmentation index (AIx)], lipids, disease activity and inflammation. Eighty-five statin-naïve patients with IJD and ultrasound-verified CP (rheumatoid arthritis: n = 53, ankylosing spondylitis: n = 24, psoriatic arthritis: n = 8) received rosuvastatin treatment for 18 months. Paired-samples t tests were used to assess ΔFMD from baseline to study end. Linear regression models were applied to evaluate correlations between ∆FMD and cardiovascular risk factors, rheumatic disease variables and medication. The mean ± SD FMD was significantly improved from 7.10 ± 3.14 % at baseline to 8.70 ± 2.98 % at study end (p < 0.001). Improvement in AIx (p < 0.05) and CP height reduction (p = 0.001) were significantly associated with ΔFMD (dependent variable). Long-term lipid lowering with rosuvastatin improved endothelial function in IJD patients with established atherosclerotic disease. Reduced arterial stiffness and CP regression were longitudinally correlated with the improvement in endothelial function measured by FMD. ClinicalTrials.gov NCT01389388 . Registered 16 April 2010.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Netherlands 1 1%
Unknown 82 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 14%
Student > Postgraduate 11 13%
Researcher 9 11%
Student > Master 8 10%
Lecturer 4 5%
Other 15 18%
Unknown 25 30%
Readers by discipline Count As %
Medicine and Dentistry 32 38%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Agricultural and Biological Sciences 3 4%
Psychology 3 4%
Other 10 12%
Unknown 29 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2015.
All research outputs
#14,620,570
of 25,506,250 outputs
Outputs from Arthritis Research & Therapy
#2,120
of 3,400 outputs
Outputs of similar age
#133,591
of 290,325 outputs
Outputs of similar age from Arthritis Research & Therapy
#63
of 94 outputs
Altmetric has tracked 25,506,250 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,400 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.